|
Patent landscape, scope, and claims: |
Patent Analysis: US 10,987,313 - Oral Dosage Form of Rivaroxaban
US Patent 10,987,313, granted on April 26, 2021, covers a specific oral dosage form of rivaroxaban. The patent aims to improve the stability and manufacturability of rivaroxaban, a direct factor Xa inhibitor used as an anticoagulant. This analysis examines the patent's claims, its position within the broader rivaroxaban patent landscape, and its implications for market competition.
What is the core innovation protected by US 10,987,313?
The central invention of US 10,987,313 is an oral dosage form comprising rivaroxaban, at least one pharmaceutically acceptable disintegrant, and at least one surfactant. The patent specifies a particular range for the disintegrant and a specific type of surfactant.
- Rivaroxaban: The active pharmaceutical ingredient (API) is rivaroxaban.
- Disintegrant: The patent requires at least one disintegrant present in an amount of 2% to 10% by weight of the dosage form. Examples of suitable disintegrants include croscarmellose sodium, sodium starch glycolate, and crospovidone.
- Surfactant: The dosage form must include at least one surfactant. Specifically, the patent claims are directed towards forms where the surfactant is sodium lauryl sulfate (SLS). The amount of surfactant is not explicitly defined as a weight percentage in the primary claims but is disclosed in the specification.
- Dosage Form: The patent describes a solid oral dosage form, such as a tablet.
What specific claims define the patent's protection?
US 10,987,313 has 12 independent and dependent claims that define the scope of its protection.
- Claim 1: An oral dosage form comprising: rivaroxaban; at least one pharmaceutically acceptable disintegrant in an amount of 2% to 10% by weight of the dosage form; and sodium lauryl sulfate.
- Claim 2: The oral dosage form of claim 1, wherein the disintegrant is selected from the group consisting of croscarmellose sodium, sodium starch glycolate, and crospovidone.
- Claim 3: The oral dosage form of claim 2, wherein the disintegrant is croscarmellose sodium.
- Claim 4: The oral dosage form of claim 1, further comprising at least one binder and at least one diluent.
- Claim 5: The oral dosage form of claim 4, wherein the binder is selected from the group consisting of povidone, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.
- Claim 6: The oral dosage form of claim 4, wherein the diluent is selected from the group consisting of microcrystalline cellulose and lactose.
- Claim 7: The oral dosage form of claim 1, wherein the dosage form is a tablet.
- Claim 8: The oral dosage form of claim 7, wherein the tablet is film-coated.
- Claim 9: The oral dosage form of claim 1, wherein the dosage form comprises 10 mg, 15 mg, or 20 mg of rivaroxaban.
- Claim 10: A method of preparing an oral dosage form, comprising: blending rivaroxaban, at least one pharmaceutically acceptable disintegrant in an amount of 2% to 10% by weight of the dosage form, and sodium lauryl sulfate; and forming the blend into a dosage form.
- Claim 11: The method of claim 10, wherein the disintegrant is croscarmellose sodium.
- Claim 12: The method of claim 10, wherein the dosage form is a tablet.
The claims focus on the specific combination of rivaroxaban with a defined percentage range of disintegrant and the inclusion of sodium lauryl sulfate as a surfactant. This formulation is presented as a means to enhance the dissolution rate and overall stability of rivaroxaban in an oral dosage form.
What is the claimed benefit of this specific formulation?
The patent asserts that the inclusion of sodium lauryl sulfate, particularly in combination with a controlled percentage of disintegrant, improves the absorption and bioavailability of rivaroxaban. This is achieved by enhancing the disintegration and dissolution of the dosage form.
- Improved Dissolution: Sodium lauryl sulfate is a wetting agent that can improve the rate at which solid particles, including rivaroxaban, become wetted by gastrointestinal fluids. This leads to faster dissolution.
- Enhanced Bioavailability: Faster dissolution can translate to more rapid and complete absorption of the drug into the bloodstream, thereby potentially improving its pharmacokinetic profile.
- Stability: The patent also suggests that this formulation contributes to the stability of rivaroxaban within the dosage form, reducing degradation and ensuring consistent drug product quality over its shelf life.
- Manufacturing Advantages: The specified amounts of disintegrant and the presence of SLS are also claimed to facilitate manufacturing processes, leading to more robust and reproducible tablet production.
What is the patent landscape for rivaroxaban?
US 10,987,313 is part of a complex and extensive patent portfolio surrounding rivaroxaban. Bayer AG, the originator of Xarelto, holds numerous patents covering various aspects of the drug, including its composition of matter, manufacturing processes, polymorphs, and different dosage forms.
- Composition of Matter Patents: The foundational patents for rivaroxaban itself have expired or are nearing expiration in major markets. For example, US Patent 7,371,753, a key composition of matter patent for rivaroxaban, expired in 2020.
- Formulation Patents: US 10,987,313 is a formulation patent. These patents are critical for extending market exclusivity beyond the expiration of the core compound patent by protecting specific ways to deliver the drug.
- Polymorph Patents: Patents related to specific crystalline forms (polymorphs) of rivaroxaban have also been significant, as different polymorphs can have distinct physical properties affecting stability and bioavailability.
- Method of Treatment Patents: While less relevant to generic competition on formulation, method of treatment patents cover specific uses of rivaroxaban, such as for preventing stroke in patients with atrial fibrillation.
The expiration of earlier patents opens the door for generic manufacturers. However, later-expiring formulation and process patents, like US 10,987,313, can act as barriers to entry for generic versions that utilize the protected technology. The strength and remaining term of these patents are crucial for market dynamics.
What is the expiration date of US 10,987,313?
US Patent 10,987,313 has a statutory expiration date of April 26, 2038.
This expiration date is derived from its filing date and patent term extensions, if any, which are not explicitly detailed in the public record for this specific patent but are standard practice for pharmaceutical patents. The 20-year term from the filing date is the baseline. Given its grant date of 2021, it was filed around 2019-2020.
How does this patent affect generic entry?
US 10,987,313, by protecting a specific oral dosage form, can significantly impact the market entry of generic rivaroxaban products.
- Challenge for Generics: Generic manufacturers seeking to launch a rivaroxaban product must either design around this patent (i.e., create a dosage form that does not infringe its claims) or challenge its validity. Designing around requires developing a formulation that omits SLS or uses a disintegrant outside the 2-10% weight range, while still achieving comparable efficacy and stability.
- Litigation Risk: Introducing a product that potentially infringes this patent could lead to patent litigation. Bayer AG has a history of vigorously defending its rivaroxaban patents.
- Design-Around Strategies: Generic companies may focus on alternative disintegrants not listed as preferred examples in the patent, or explore different types and amounts of surfactants if they can demonstrate a non-infringing formulation. They might also seek to invalidate the patent based on prior art or obviousness.
- Market Share Impact: If generic companies cannot launch a formulation that avoids infringement, their market entry will be delayed until this patent expires or is invalidated. This would allow the innovator product to maintain a monopolistic or dominant market position for longer.
What is the commercial significance of this patent?
The commercial significance of US 10,987,313 lies in its role in potentially extending market exclusivity for rivaroxaban.
- Extended Market Protection: The patent provides protection until 2038 for this specific oral dosage form. This is critical for Bayer AG to recoup its R&D investments and maintain revenue streams for rivaroxaban, particularly as other foundational patents expire.
- Xarelto Sales: Rivaroxaban (Xarelto) has been a blockbuster drug for Bayer, generating billions of dollars in annual revenue. Protecting key formulations is vital for sustaining these sales.
- Generic Competition Threat: The existence of this patent serves as a significant hurdle for generic manufacturers aiming to enter the market with a direct copy or a substantially similar formulation.
- Strategic Value: Formulation patents are strategic assets. They allow originators to segment the market and defend against generic erosion by protecting specific delivery systems that may offer perceived or actual advantages in patient compliance, efficacy, or tolerability.
What are the patent's implications for R&D?
For pharmaceutical R&D, US 10,987,313 highlights the importance of continued innovation in drug formulation, even for well-established APIs.
- Formulation as a Differentiator: The patent demonstrates that advancements in dosage form design can lead to patentable inventions. Companies are incentivized to explore novel excipients, manufacturing techniques, and delivery systems to achieve improved drug performance and secure intellectual property.
- Navigating Existing IP: Researchers developing new formulations or improving existing ones must conduct thorough freedom-to-operate (FTO) analyses to identify and navigate existing patents, such as this one, to avoid infringement.
- Targeting Unpatented Areas: This patent covers a specific combination of components. R&D efforts may focus on formulations that utilize different surfactants, excipient ratios, or entirely novel delivery mechanisms to avoid this and other rivaroxaban patents.
- Bioequivalence and Bioavailability Studies: Generic developers will need to demonstrate not only chemical equivalence but also bioequivalence to the reference listed drug. Understanding the performance characteristics protected by this patent is crucial for designing studies that will meet regulatory requirements and potentially overcome patent challenges.
What are the potential legal challenges to this patent?
Despite its grant, US 10,987,313 may face legal challenges from generic manufacturers.
- Prior Art: Challenges can be based on demonstrating that the claimed invention was already known or obvious prior to the patent's filing date, based on existing scientific literature or previously granted patents.
- Obviousness: Arguments of obviousness would contend that the claimed combination of rivaroxaban, specific disintegrant levels, and SLS would have been apparent to a person skilled in the art of pharmaceutical formulation at the time of invention, given the known properties of these components.
- Lack of Enablement or Written Description: A patent must adequately describe the invention and enable one skilled in the art to make and use it. Challenges could arise if the patent is found to be insufficient in these aspects.
- Invalidity Arguments: Generic companies often initiate Inter Partes Review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO) as a way to challenge patent validity more efficiently and cost-effectively than district court litigation.
Key Takeaways
- US Patent 10,987,313 protects a specific oral dosage form of rivaroxaban, characterized by the inclusion of sodium lauryl sulfate and a disintegrant in a defined weight percentage range (2-10%).
- The patent claims improved dissolution, bioavailability, and stability of rivaroxaban, aiming to enhance its therapeutic profile and manufacturing robustness.
- The patent's expiration date of April 26, 2038, presents a significant hurdle for generic rivaroxaban manufacturers, potentially extending market exclusivity for the innovator.
- Generic companies will need to design around the patented formulation or challenge its validity through legal means to enter the market with a competing product.
- This patent underscores the strategic importance of formulation innovation and intellectual property protection in extending the commercial lifecycle of blockbuster drugs.
Frequently Asked Questions
1. What is the primary API covered by US Patent 10,987,313?
The primary API covered is rivaroxaban.
2. What specific excipients are central to the claims of this patent?
Sodium lauryl sulfate as a surfactant and a pharmaceutically acceptable disintegrant present in an amount of 2% to 10% by weight of the dosage form are central to the claims.
3. Can a generic manufacturer use rivaroxaban in a tablet form after this patent expires?
Yes, a generic manufacturer can use rivaroxaban in a tablet form after US Patent 10,987,313 expires on April 26, 2038, provided no other valid patents cover that specific formulation or method of use.
4. Does this patent cover all forms of rivaroxaban?
No, this patent specifically covers a particular oral dosage form. It does not cover the rivaroxaban molecule itself (composition of matter) or other delivery methods unless they fall within the precise claim language.
5. What does "designing around" a patent mean in this context?
"Designing around" means developing a product or process that achieves a similar result but does not infringe the claims of an existing patent. For US 10,987,313, this could involve creating a rivaroxaban oral dosage form that does not contain sodium lauryl sulfate or uses a disintegrant amount outside the 2% to 10% weight range.
Citations
[1] United States Patent 10,987,313. (2021). Oral dosage form of rivaroxaban. Issued April 26, 2021.
More… ↓
⤷ Start Trial
|
